Five years ago, pharmaceutical company (NASDAQ: MRNA) was mostly unknown. It was developing vaccines that induce human immune cells to more effectively fight disease. But the science of DNA-based drugs was on the experimental fringe of the biopharma landscape. Not too many investors were looking to make such a bet.

Then the COVID-19 pandemic materialized. As it turns out, the coronavirus was the ideal target for Moderna's biotechnology. In December 2020, the U.S. Food and Drug Administration approved its COVID vaccine for emergency use. Other nations' regulatory bodies followed suit.

The rest, as they say, is history.

Continue reading

Source Fool.com